Tag
Reprogramming glutamine metabolism via Asct2 transporter expression improves BCMA-CAR T cell fitness, proliferation, and anti-myeloma efficacy under glutamine-limited conditions, offering a promising strategy to overcome metabolic immune ev
A response-adapted trial of daratumumab monotherapy in elderly newly diagnosed multiple myeloma reveals key biomarkers—CD38 expression, plasma cell phenotype, and immune microenvironment—that predict treatment sensitivity and inform therape
A registry analysis in Germany reveals superior remission conversion and progression-free survival with ciltacabtagene autoleucel compared to idecabtagene vicleucel in heavily pretreated multiple myeloma, supporting individualized CAR T the
Circulating tumor cells (CTCs) serve as an independent prognostic biomarker in transplant-eligible newly diagnosed multiple myeloma patients treated with daratumumab-based quadruplet therapy, predicting progression-free survival and minimal
The phase 3 GEM12 trial compares busulfan-melphalan versus melphalan conditioning in ASCT for newly diagnosed multiple myeloma, showing longer PFS with busulfan-melphalan after intensified VRD induction and consolidation, especially in adva
A meta-analysis of 24 trials involving 13,926 patients establishes that concurrent high-risk cytogenetic abnormalities markedly worsen progression-free and overall survival in both newly diagnosed and relapsed multiple myeloma, underscoring
The REST trial demonstrated that combining isatuximab with weekly bortezomib, lenalidomide, and limited dexamethasone yields promising efficacy and manageable safety in older patients with transplant-ineligible multiple myeloma.
FCARH143, a fully human BCMA-directed CAR-T cell therapy, shows remarkable long-term efficacy and manageable safety profile in heavily pretreated relapsed/refractory multiple myeloma patients over 5 years.
Clonal hematopoiesis (CH) occurs frequently in patients receiving CD19 or BCMA CAR T therapy and correlates with a higher risk of severe cytokine release syndrome (CRS), suggesting CH as a potential biomarker for CRS risk and a target for p
This phase 2 trial evaluated modakafusp alfa, a novel immunocytokine targeting CD38+ cells, in heavily pretreated relapsed/refractory multiple myeloma, showing promising efficacy and manageable toxicity despite early termination.
A secondary analysis of three total therapy clinical trials reveals significant long-term survival improvements in multiple myeloma patients with modern combinational and stem cell transplant approaches incorporating immunomodulatory and pr
The IRAKLIA Phase III trial found that subcutaneous isatuximab via on-body injector is noninferior to intravenous administration in efficacy and safety for relapsed/refractory multiple myeloma.
Long-term CASSIOPEIA results confirm daratumumab plus VTd induction/consolidation and daratumumab maintenance deliver deepest MRD negativity and superior PFS in transplant-eligible, newly diagnosed myeloma.
Final BELLINI trial results show improved progression-free survival with venetoclax in relapsed/refractory multiple myeloma, but increased early mortality negates overall survival benefit, prompting caution for general use.
KRd and D-KRd regimens outperform VMP 9-Rd 9 in achieving deeper responses in older, fit, transplant-ineligible multiple myeloma patients, but toxicity remains a concern, particularly with quadruplet therapy.
The EMN20 phase 3 trial demonstrates that adding carfilzomib to lenalidomide-dexamethasone significantly increases MRD negativity and progression-free survival in transplant-ineligible newly diagnosed multiple myeloma, with manageable toxic
The DREAMM-7 trial demonstrates that belantamab mafodotin with bortezomib and dexamethasone significantly improves survival in relapsed/refractory multiple myeloma, suggesting a new standard of care.
A recent J Clin Oncol study shows that nearly 33% of RRMM patients treated with cilta-cel achieved ≥5 years of progression-free survival, highlighting durable responses and promising biomarkers.
MRD-guided consolidation strategies in transplant-eligible multiple myeloma patients did not significantly improve deep remission rates over conventional approaches, questioning the clinical utility of MRD-adapted intensification.
